Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom

Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study ID
NCT07239596
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Renal Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study evaluated the safety and efficacy of SHR-8068 in combination with Adebrelimab and other anti-tumor drugs in the treatment of advanced renal cell carcinoma

Key Dates

First listed
Nov 20, 2025
Start date
Jan 6, 2026
Status verified
Nov 2025
Primary completion
Dec 31, 2030
Completion
Dec 31, 2030

Study Design

Enrollment
139 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-8068+ Adebrelimab + Bevacizumab
  • Experimental: SHR-8068+ Adebrelimab +HS-10516
  • Experimental: SHR-8068+ Adebrelimab + Bevacizumab +HRS-10516

Primary Outcome Measure

Dose-limiting toxicity (DLT) [ Time Frame: 21days after the first administration of each subject ]

Central Contacts

Related Studies